| Date | Title | Description | |
|---|---|---|---|
| 12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 13 May 2021 | On business and financial situation | ROVI releases the first quarter 2021 results presentation | Download |
| 13 May 2021 | Announcement of general shareholders’ meeting | Rovi releases the information related to its 2021 General Shareholders Meeting | Download |
| 06 Apr 2021 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the first quarter of 2021 | Download |
| 24 Feb 2021 | On business and financial situation | The company releases the press release related to 2020 financial results | Download |
| 24 Feb 2021 | On business and financial situation | ROVI releases the 2020 Results presentation | Download |